AR045654A1 - Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico - Google Patents

Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico

Info

Publication number
AR045654A1
AR045654A1 ARP040103296A ARP040103296A AR045654A1 AR 045654 A1 AR045654 A1 AR 045654A1 AR P040103296 A ARP040103296 A AR P040103296A AR P040103296 A ARP040103296 A AR P040103296A AR 045654 A1 AR045654 A1 AR 045654A1
Authority
AR
Argentina
Prior art keywords
methylethyl
fluorophenyl
phenyl
heptanoic
dihydroxi
Prior art date
Application number
ARP040103296A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR045654A1 publication Critical patent/AR045654A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Se describen nuevas formas cristalinas de ácido [R-(R*, R*)]-2-(4-fluorofenil)-beta, gamma-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1H-pirrol-1-heptanoico (ácido libro atorvastatina) designadas Forma A y forma B, caracterizada por su patrón de difracción de rayos X en polvo y sus espectros NMR en estado sólido, así como métodos para la preparación y composición farmacéutica de las mismas, que son útiles como agentes para el tratamiento de hiperlipidemia, hipercolesterolemia, osteoporosis, hiperplasia protática benigna, y enfermedad de alzhemer, y para prepara sales de atorvastatina.
ARP040103296A 2003-09-17 2004-09-15 Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico AR045654A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50359203P 2003-09-17 2003-09-17

Publications (1)

Publication Number Publication Date
AR045654A1 true AR045654A1 (es) 2005-11-02

Family

ID=34312443

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103296A AR045654A1 (es) 2003-09-17 2004-09-15 Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico

Country Status (16)

Country Link
US (1) US20070276027A1 (es)
EP (1) EP1663969A1 (es)
JP (1) JP2007505885A (es)
KR (1) KR100781420B1 (es)
CN (2) CN101318923A (es)
AR (1) AR045654A1 (es)
AU (1) AU2004272365A1 (es)
BR (1) BRPI0414457A (es)
CA (1) CA2539158A1 (es)
IL (1) IL173651A0 (es)
MX (1) MXPA06003003A (es)
NO (1) NO20060716L (es)
RU (1) RU2315755C2 (es)
TW (1) TW200524862A (es)
WO (1) WO2005026116A1 (es)
ZA (1) ZA200602222B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200745026A (en) 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
NZ579736A (en) * 2007-04-13 2012-02-24 Nicox Sa Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester
US8697740B2 (en) 2009-01-12 2014-04-15 Merck Sharp & Dohme Corp. Crystalline polymorphic forms of an antidiabetic compound
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
CA3065589C (en) 2010-06-03 2022-04-26 Catalent Ontario Limited Multi phase soft gel capsules, apparatus and method thereof
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5213995A (en) * 1992-04-16 1993-05-25 At&T Bell Laboratories Method of making an article comprising a periodic heteroepitaxial semiconductor structure
CA2150372C (en) * 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
SI0848705T1 (en) * 1995-07-17 2002-04-30 Warner-Lambert Company Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5998633A (en) * 1996-07-29 1999-12-07 Warner-Lambert Company Process for the synthesis of protected esters of (S)-3,4-dihydroxybutyric acid
WO1999032434A1 (en) * 1997-12-19 1999-07-01 Warner-Lambert Export Limited Process for the synthesis of 1,3-diols
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
PL362981A1 (en) * 2000-11-16 2004-11-02 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide

Also Published As

Publication number Publication date
RU2315755C2 (ru) 2008-01-27
AU2004272365A1 (en) 2005-03-24
CA2539158A1 (en) 2005-03-24
CN101318923A (zh) 2008-12-10
KR20060037467A (ko) 2006-05-03
KR100781420B1 (ko) 2007-12-03
JP2007505885A (ja) 2007-03-15
IL173651A0 (en) 2006-07-05
BRPI0414457A (pt) 2006-11-14
RU2006108385A (ru) 2006-08-10
MXPA06003003A (es) 2006-06-23
WO2005026116A1 (en) 2005-03-24
EP1663969A1 (en) 2006-06-07
CN1852894A (zh) 2006-10-25
NO20060716L (no) 2006-06-16
US20070276027A1 (en) 2007-11-29
ZA200602222B (en) 2007-07-25
TW200524862A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
AR003458A1 (es) Forma cristalina de atorvastatina o hidrato de la misma y composicion farmaceutica que la comprende.
WO2005105738A3 (en) Salt forms of atorvastatin
RS100003A (en) Crystalline forms of /r-(r*,r*)-2-(4- fluorphenyl)-beta,delta -dihydroxy-5(1- methylethyl)-phenyl-4-/phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
ATE207465T1 (de) Kristalline form iii des hemi calcium salzes von (r-(r*,r*))-2-(4-fluorphenyl)-beta-delta- dihydroxy-5-(1-methylethyl)-3-phenyl-4- ((phenylamino)carbonyl)-1h-pyrrol-1-heptansäure (atorvastatin)
DK0839132T5 (da) Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1)
BR0116785A (pt) Processo para a sìntese da forma v de atorvastatina e fenilboronatos como compostos intermediários
NZ533935A (en) Crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-heptanoic acid calcium salt (2:1)
TW200738624A (en) Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
AR045654A1 (es) Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico
WO2006011041A3 (en) Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
HUP0600120A2 (en) New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it
CA2521908A1 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
PL349307A1 (en) Novel crystalline form of semi-calcium [r-(r ,r)]-2-(4-fluorophenyl)-beta, dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl)-1h-pyrrole-1-heptanic salt (athorovastatin), method of obtaining same, pharmacological composition containing such salt and medical application thereof
CY1110165T1 (el) Νεες μορφες αλατος μαγνησιου του [r-(r*,r*)]-2-(4-φθοροφαινυλ)-β,β-διυδροξυ-5-(1-μεθυλαιθυλ)-3-5 φαινυλ-4-[(φαινυλαμινο)καρβονυλ]-1η-πυρρολο-1-επτανοϊκου οξεος
UY27608A1 (es) Formas cristalinas hidratadas de atorvastatina forma ii y forma iv.

Legal Events

Date Code Title Description
FB Suspension of granting procedure